Skip to main content

Advertisement

SpringerLink
Log in

Novel Treatments for Diabetic Macular Edema and Proliferative Diabetic Retinopathy

  • Microvascular Complications—Retinopathy (R Channa, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Diabetic retinopathy (DR), a common cause of vision loss, is projected to increase worldwide, and is associated with significant morbidity. The current standard-of-care treatments can preserve and significantly improve vision in many patients affected by DR. However, challenges such as heavy treatment burden and refractory disease remain. The purpose of this review is to highlight and discuss investigative agents in development for the treatment of DR.

Recent Findings

There are several novel agents with unique mechanisms that may offer greater durability and efficacy compared to existing drugs. Some target new pathways, others leverage a slow-release delivery system, and some modify gene expression through a single-dose treatment.

Summary

While unfavorable adverse events, such as intraocular inflammation, have been observed with longer-durability agents, many investigational products show excellent efficacy and safety profiles. The outcomes of ongoing and future trials may revolutionize the current treatment paradigm for DR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14:179–83.

    Article  PubMed  Google Scholar 

  2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.

    Article  CAS  PubMed  Google Scholar 

  3. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Romero-Aroca P. Targeting the pathophysiology of diabetic macular edema. Diabetes Care. 2010;33(11):2484–5. https://doi.org/10.2337/dc10-1580.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102(4):647–61.

    Article  Google Scholar 

  6. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet. 1998;352(9131):837–53.

    Article  Google Scholar 

  7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13.

    Article  PubMed Central  Google Scholar 

  8. Photocoagulation for diabetic macular edema. ETDRS Report Number 1 Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1985;103(12):1796–806. https://doi.org/10.1001/archopht.1985.01050120030015.

    Article  Google Scholar 

  9. The Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-1077. E35. https://doi.org/10.1016/j.ophtha.2010.02.031.

    Article  Google Scholar 

  10. Nguyen QD, Brown DM, Marcus DM, Boyer DS, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. https://doi.org/10.1016/j.ophtha.2011.12.039.

    Article  PubMed  Google Scholar 

  11. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. A phase II randomized clinical trial of IVT bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860–1187.

    Article  Google Scholar 

  12. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, et al. A 2-year prospective randomized controlled trial of IVT bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972–9.

    Article  CAS  PubMed  Google Scholar 

  13. Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, et al. IVT Aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376–85. https://doi.org/10.1016/j.ophtha.2016.07.032.

    Article  PubMed  Google Scholar 

  14. Wells JA, Glassman AR, Ayala AR, Jampol LM, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–9. https://doi.org/10.1016/j.ophtha.2016.02.022.

    Article  PubMed  Google Scholar 

  15. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, et al. Three-year, randomized, sham-controlled trial of dexamethasone IVT implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–14. https://doi.org/10.1016/j.ophtha.2014.04.024.

    Article  PubMed  Google Scholar 

  16. Campochiaro PA, Brown DM, Pearson A, Fiulla T, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626-635.e2. https://doi.org/10.1016/j.ophtha.2010.12.028.

    Article  PubMed  Google Scholar 

  17. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology. 1978;85(1):82–106. https://doi.org/10.1016/s0161-6420(78)35693-1.

    Article  Google Scholar 

  18. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy ETDRS report number 9. Ophthalmology. 1991;98(5 Suppl):766–85.

    Google Scholar 

  19. Diabetic Retinopathy Study Research Group. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2013;314(20):2137–46. https://doi.org/10.1001/jama.2015.15217.

    Article  CAS  Google Scholar 

  20. CLARITY Study Group. Clinical efficacy of IVT aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389(10085):2193–203. https://doi.org/10.1016/S0140-6736(17)31193-5.

    Article  Google Scholar 

  21. Gonzalez VH, Campbell J, Holekamp NM, Kiss S, et al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of Protocol I data. Am J Ophthalmol. 2016;172:72–9. https://doi.org/10.1016/j.ajo.2016.09.012.

    Article  CAS  PubMed  Google Scholar 

  22. Reddy SV, Husain D. Panretinal photocoagulation: a review of complications. Semin Ophthalmol. 2018;33(1):83–8. https://doi.org/10.1080/08820538.2017.1353820.

    Article  PubMed  Google Scholar 

  23. •• Dugel PU, Singh RP, Koh A, Tadayoni R, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;128(1):89–99. https://doi.org/10.1016/j.ophtha.2020.06.028. This study provides evidence that brolucizumab is noninferior to aflibercept in the treatment of nAMD and potentially offers greater durability, but was also associated with higher rates of anterior chamber inflammation.

    Article  PubMed  Google Scholar 

  24. Novartis halts three trials of Beovu eye drug on safety concerns. https://pharmaphorum.com/news/novartis-halts-three-trials-of-beovu-eye-drug-on-safety-concerns/. Cited 07/05/21.

  25. Garweg JG. A randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in patients with visual impairment due to Diabetic Macular Edema (KITE). Klin Monbl Augenheilkd. 2020;237(4):450–3. https://doi.org/10.1055/a-1101-9126.

    Article  PubMed  Google Scholar 

  26. Novartis Pharmaceuticals: study of efficacy and safety of brolucizumab vs. aflibercept in patients with visual impairment due to Diabetic Macular Edema (KESTREL). In: ClinicalTrials.gov. Cited 12/23/20.

  27. Novartis Phase III Beovu data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept. https://pharmaphorum.com/news/novartis-halts-three-trials-of-beovu-eye-drug-on-safety-concerns/. Cited 07/05/21.

  28. Novartis Pharmaceuticals: a 12-month, 2-arm, randomized, double-masked, multicenter phase III study assessing the efficacy and safety of brolucizumab vs. aflibercept in patients with visual impairment due to diabetic macular edema (KINGFISHER). In: Clinicaltrials.gov. Cited 01/03/20.

  29. Novartis Pharmaceuticals: a one-year, randomized, double-masked, multicenter, phase III, two-arm study assessing the efficacy and safety of brolucizumab versus aflibercept in adult Chinese patients with visual impairment due to diabetic macular edema (KINGLET). In: Clinicaltrial.gov. Cited 01/03/20.

  30. Novartis Pharmaceuticals: efficacy and safety of brolucizumab vs. aflibercept in patients with visual impairment due to diabetic macular edema (BUZZARD). In: ClinicalTrials.gov. Cited 12/23/20.

  31. Liang H, Huang X, Ngo W, Dang D, et al. KSI-301: An anti-VEGF antibody biopolymer conjugate with extended half-life for treatment of neovascular retinal diseases. Invest Ophthalmol Vis Sci. 2018;59(9):211.

    Google Scholar 

  32. Patel SS, Naor J, Qudrat A, Do DV, et al. Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durability. Invest Ophthalmol Vis Sci. 2019;60(9):3670.

    Google Scholar 

  33. Do D. Extended durability in exudative retinal diseases using the novel intravitreal anti-VEGF antibody biopolymer conjugate KSI-301. In: Angiogenesis, Exudation, and Degeneration 2021 Meeting. Miami, FL, United States. 2021; Ir. Kodiak.com/events-and-presentations/events.

  34. Two studies in diabetic macular edema and one study in macular edema due to retinal vein occlusions. https://www.prnewswire.com/news-releases/kodiak-sciences-treats-first-patients-in-three-phase-3-studies-of-ksi-301--two-studies-in-diabetic-macular-edema-and-one-study-in-macular-edema-due-to-retinal-vein-occlusion-301145454.html. Cited 01/02/21.

  35. Inspired to build the world’s leading high-science retina pipeline. https://kodiak.com/our-pipeline/. Cited 01/02/21.

  36. REGENXBIO announces additional positive interim phase I/IIa trial update and program updates for RGX-314 for the treatment of wet AMD. http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-additional-positive-interim-phase-iiia-0. Cited 03/07/21.

  37. REGENXBIO announces dosing first patient in phase II ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy using suprachoroidal delivery. https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-dosing-first-patient-phase-ii-altitudetm. Cited 01/03/21.

  38. Adverum biotechnologies announces positive interim data from cohorts 1–4 from OPTIC phase 1 trial of ADVM-022 intravitreal gene therapy for wet AMD. https://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-announces-positive-interim-data-0. Cited 03/07/21.

  39. Adverum Biotechnologies announces new INFINITY Phase 2 Trial for ADVM-022 in diabetic macular edema. https://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-announces-new-infinity-phase-2-trial. Cited 01/10/21.

  40. Campochiaro P. Primary analysis results of the Phase 3 ARCHWAY trial of the Port Delivery System with ranibizumab (PDS) for patients with neovascular AMD. American Society of Retina Specialists 2020 Virtual Annual Meeting; 2020.

  41. Freeman WR, Gune S, Barteselli G. Optimization of the Port Delivery System with ranibizumab (PDS) implant insertion procedure in the ladder phase 2 trial. Invest Ophthalmol Vis Sci. 2020;61(7):3703.

    Google Scholar 

  42. •• Campochiaro PA, Marcus DM, Awh CC, Regillo C, et al. The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial. Ophthalmology. 2019;126(8):1141–54. https://doi.org/10.1016/j.ophtha.2019.03.036. This phase 2 study demonstrated comparable visual and anatomic outcomes as well as significant reduced injection burden in patients with nAMD treated with PDS versus patients treated with monthly ranibizumab injections. There were improved rates of vitreous hemorrhage following surgical procedure modification.

    Article  PubMed  Google Scholar 

  43. Khanani AM, Callanan D, Dreyer D, Tam T, et al. End-of-study results for the ladder phase 2 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration. Ophthalmology Retina.https://doi.org/10.1016/j.oret.2020.11.004

  44. Hoffmann-La Roche. A phase III, multicenter, randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with diabetic macular edema (Pagoda). In: ClinicalTrials.gov. Cited 01/24/21.

  45. A multicenter, randomized study in participants with diabetic retinopathy without center-involved diabetic macular edema to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered via the port delivery system relative to the comparator arm (PAVILION). In: Clinicaltrials.gov. Cited 03/08/21.

  46. Dugel PU, Boyer DS, Antoszyk AN, Steinle NC, et al. Phase 1 study of OPT-302 inhibition of vascular endothelial growth factors C and D for neovascular age-related macular degeneration. Ophthalmol Retina. 2020;4(3):250–2633. https://doi.org/10.1016/j.oret.2019.10.008.

    Article  PubMed  Google Scholar 

  47. Opthea reports positive phase 1a trial results of OPT-302. https://www.biospace.com/article/releases/opthea-reports-positive-phase-2a-trial-results-of-opt-302-in-diabetic-macular-edema/. Cited 01/17/21.

  48. Opthea limited: a dose ranging study of OPT-302 with aflibercept for persistent diabetic macular edema. In: Clinicaltrials.gov. Cited 01/17/21.

  49. •• Sahni J, Patel SS, Dugel PU, Khanani AM, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126(8):11551170. https://doi.org/10.1016/j.ophtha.2019.03.023. This phase 2 study demonstrated statistically superior visual outcomes in treatment-naïve patients with DME when treated with faricimab compared to ranibizumab at week 24.

    Article  Google Scholar 

  50. A study to evaluate the efficacy and safety of faricimab (RO6867461) in participants with diabetic macular edema (YOSEMITE). In: ClinicalTrials.gov. Cited 01/19/21.

  51. A study to evaluate the efficacy and safety of faricimab (RO6867461) in participants with diabetic macular edema (RHINE). In: ClinicalTrials.gov. Cited 01/19/21.

  52. Genentech has announced more detailed data from 4 phase 3 studies that further support faricimab’s ability to extend time between treatments for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). https://www.hcplive.com/view/genentech-announces-fuller-data-supporting-faricimab--dme-namd. Cited 03/08/21.

  53. Wykoff CC, Abreu F, Basu K, Haskova Z, et al. Faricimab in diabetic macular edema YOSEMITE AND RHINE study results. In: Angiogenesis, Exudation, and Degeneration 2021 Meeting. Miami, FL, United States. https://medically.gene.com/global/en/unrestricted/ophthalmology/ANGIOGENESIS-2021/angiogenesis-2021-presentation-wykoff-phase-3-dme-yosem.html.

  54. Liu K, Song Y, Xu G, Ye J, et al. Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol. 2019;197:156–67. https://doi.org/10.1016/j.ajo.2018.08.026.

    Article  CAS  PubMed  Google Scholar 

  55. Lu Q, Li L, Bin C, Wei C, PeiRong L. Efficacy comparison of IVT injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy. Can J Ophthalmol. 2019;54(3):291–6. https://doi.org/10.1016/j.jcjo.2018.06.010.

    Article  PubMed  Google Scholar 

  56. Li B, Li M, Ye J, Chen Z, Guo Z, Di Y. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after IVT injection of conbercept as an adjunctive therapy for vitrectomy. Chin Med J (Engl). 2020;133(6):664–9. https://doi.org/10.1097/CM9.0000000000000687.

    Article  Google Scholar 

  57. Xu Y, Rong A, Bi Y, Xu W. IVT conbercept injection with and without grid laser photocoagulation in the treatment of diffuse diabetic macular edema in real-life clinical practice. J Ophthalmol. 2016;2016:2143082. https://doi.org/10.1155/2016/2143082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. •• Liu W, Li Y. Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a meta-analysis and systematic review. Int J Ophthalmol. 2019;12(9):1479–86. https://doi.org/10.18240/ijo.2019.09.17. This meta-analysis showed that conbercept was superior to ranibizumab in anatomic outcomes in patients with DME. Visual outcomes, however, showed no statistically significant difference.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Safety and efficacy by multiple injection of KH902 in patients with diabetic macular edema (DME) (Frontier-1). In: ClinicalTrials.gov. Cited 03/13/21.

  60. Safety and efficacy study of conbercept in diabetic macular edema (DME) (Sailing). In ClinicalTrials.gov.Cited 03/13/21.

  61. Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: “Is there a big change on the horizon?” Clin Ophthalmol. 2018;12:2137–43. https://doi.org/10.2147/OPTH.S180393.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Sharma S, RE-ENACT 2 Study Investigators Group, Skan MA, Chaturvedi A. A multicenter, retrospective study (RE-ENACT 2) on the use of RazumabTM (World’s First Biosimilar Ranibizumab) in Wet AMD, DME, RVO and Myopic CNV. Clin Exp Ophthalmol. 2019;10(5):826.

    Google Scholar 

  63. Dry and wet age-related macular degeneration - special topics - special topics: biosimilar anti-VEGF agents (US). https://decisionresourcesgroup.com/report/sptoop0001-biopharma-diabetic-macular-edema-diabetic-retinopathy/. Cited 01/21/21.

  64. Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann B, Loewenstein A. Biosimilars for retinal diseases: an update. Am J Ophthalmol. 2021;224:36–42.

    Article  CAS  PubMed  Google Scholar 

  65. Campochiaro PA, Channa R, Berger BB, Heier JS, et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2013;155(4):697-704.e1–2. https://doi.org/10.1016/j.ajo.2012.09.032.

    Article  CAS  PubMed  Google Scholar 

  66. Abicipar Pegol PALM Study Phase 2 Data in Diabetic Macular Edema Presented at 2016 AAO Annual Meeting. https://www.molecularpartners.com/abicipar-pegol-palm-study-phase-2-data-in-diabetic-macular-edema-dme-presented-at-2016-aao-annual-meeting/. Cited 01/18/21.

  67. •• Khurana RN, Kunimoto D, Yoon YG, Wykoff CC, et al. Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration. Ophthalmology. 2020;S0161–6420(20)31109-X. https://doi.org/10.1016/j.ophtha.2020.11.017. This phase 3 study showed that patients with nAMD treated with abicipar every 8 or 12 weeks had comparable vision and anatomic outcomes compared to patients treated with monthly ranibizumab. However, there was a higher incidence of intraocular inflammation in the abicipar groups.

  68. Allergan and molecular partners announce topline safety results from MAPLE study of Abicipar pegol. Available at: https://www.molecularpartners.com/allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol/. Published 2019. Cited 01/18/21.

  69. The FDA does not approve Allergan’s wet AMD drug candidate Abicipar Pegol. Available at: https://eyewire.news/articles/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol/. Cited 01/18/21.

  70. Graybug vision presents top line results of phase 1/2a ADAGIO study at Hawaiian Eye & Retina 2019. https://www.businesswire.com/news/home/20190121005424/en/Graybug-Vision-Presents-Top-Line-Results-of-Phase-12a-ADAGIO-Study-at-Hawaiian-Eye-Retina-2019. Cited 01/18/21.

  71. Graybug Vision. A depot formulation of Sunitinib Malate (GB-102) in subjects with diabetic macular edema and retinal vein occlusion. In: ClinicalTrials.gov. Cited 01/18/21.

  72. Our technologies and pipeline. https://www.graybug.vision/our-technologies-and-pipeline/gb-103/#gb103. Cited 01/18/21.

  73. Abdouh M, Talbot S, Couture R, Hassessian HM. Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B1 and B2 receptors. Br J Pharmacol. 2008;154(1):136–214. https://doi.org/10.1038/bjp.2008.48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Teufel DP, Bennett G, Harrison H, Rietschoten KV, et al. Stable and long-lasting, novel bicyclic peptide plasma kallikrein inhibitors for the treatment of diabetic macular edema. J Med Chem. 2018;61(7):2823–36. https://doi.org/10.1021/acs.jmedchem.7b01625.

    Article  CAS  PubMed  Google Scholar 

  75. Dugel P. Results of a phase 1, open-label, dose-escalation study of THR-149 for the treatment of DME. Retina Society. London; 2019.

  76. First patient dosed in phase 2 study evaluating THR-149 for treatment of DME. https://www.oxurion.com/product/thr-149-pkal-inhibitor. Cited 01/20/21.

  77. Oxurion NV reports first patient dosed in phase 2 study evaluating THR-149 for treatment of diabetic macular edema (DME). https://www.globenewswire.com/news-release/2020/09/01/2086561/0/en/Oxurion-NV-Reports-First-Patient-Dosed-in-Phase-2-study-evaluating-THR-149-for-treatment-of-Diabetic-Macular-Edema-DME.html. Cited 03/13/21.

  78. Hu T, Vanhove M, Porcu M, Hove I, et al. The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders. Exp Eye Res. 2019;180:43–52. https://doi.org/10.1016/j.exer.2018.11.022.

    Article  CAS  PubMed  Google Scholar 

  79. Oxurion reports positive topline data from phase 1 study of THR-687 for treatment of DME. https://eyewire.news/articles/oxurion-nv-reports-positive-topline-data-from-phase-1-study-evaluating-thr-687-for-treatment-of-dme/. Cited 03/27/21.

  80. Henry HH, Bavik C, Lieu KL, Pashko A, et al. Emixustat hydrochloride for the potential treatment of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2014;55(13):1061.

    Google Scholar 

  81. Emixustat for proliferative diabetic retinopathy. https://www.kubotavision.com/pipeline/development/pdr/index.html. Cited 01/22/21.

  82. Kubota R, Jhaveri C, Koester JM, Gregory JK. Effects of emixustat hydrochloride in patients with proliferative diabetic retinopathy: a randomized, placebo-controlled phase 2 study. Graefes Arch Clin Exp Ophthalmol. 2020.https://doi.org/10.1007/s00417-020-04899-y

  83. Carbajal K, Weksler M, Moore L, Ding J, Kopcynski C, Lin C. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2018;59(9):200.

    Google Scholar 

  84. Aerie Pharmaceuticals. First-in-human study of the safety of AR-13503 sustained release IVT implant in subjects with neovascular age-related macular degeneration (nAMD) and subjects with diabetic macular edema (DME) In: ClinicalTrials.gov. Cited 01/22/21.

  85. Saeedi P, Petersohn I, Salpea P, Bright D, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157. https://doi.org/10.1016/j.diabres.2019.107843.

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, 1977 Butler Blvd, Houston, TX, 77030, USA

    Nhon T. Le, Zachary A. Kroeger & Christina Y. Weng

  2. Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA

    Weijie Violet Lin

  3. Sierra Eye Associates, Reno, NV, USA

    Arshad M. Khanani

  4. Reno School of Medicine, The University of Nevada, Reno, NV, USA

    Arshad M. Khanani

Authors
  1. Nhon T. Le
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zachary A. Kroeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weijie Violet Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arshad M. Khanani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christina Y. Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina Y. Weng.

Ethics declarations

Conflict of Interest

NTL: none; ZAK: none; WVL: none; AMK: Adverum, Aerpio, Alcon, Allergan, Dutch Ophthalmic Research Center, Genentech, Inc., Iveric Bio, Kato Pharmaceuticals, Kodiak Sciences Inc., Novartis, Gemini Therapeutics, Graybug, Gyroscope, Opthea, Oxurion, PolyPhotonix, Recens Medical, Regenxbio (consultant); Adverum, Alkahest, Allergan, Allegro, Gemini Therapeutics, Genentech, Inc., Gyroscope, Iveric Bio, NGM pharmaceuticals, Kodiak Sciences Inc., Novartis, Opthea, Ophthotech, Oxurion, Regenxbio, Recens Medical (research support); Allergan, Genentech and Novartis (speaker); CYW: Alcon, Allergan/AbbVie, Alimera Sciences, Novartis, Genentech, Regeneron, REGENXBIO, Dutch Ophthalmic Research Center (consultant).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Microvascular Complications—Retinopathy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Le, N.T., Kroeger, Z.A., Lin, W.V. et al. Novel Treatments for Diabetic Macular Edema and Proliferative Diabetic Retinopathy. Curr Diab Rep 21, 43 (2021). https://doi.org/10.1007/s11892-021-01412-5

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11892-021-01412-5

Keywords

Search

Navigation